- Home
- FYBR vs VRNA Comparison
FYBR vs VRNA Comparison
Compare FYBR & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FYBR
- VRNA
- Stock Information
- Founded
- FYBR 1935
- VRNA 2005
- Country
- FYBR United States
- VRNA United Kingdom
- Employees
- FYBR N/A
- VRNA N/A
- Industry
- FYBR Telecommunications Equipment
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- FYBR Consumer Discretionary
- VRNA Health Care
- Exchange
- FYBR Nasdaq
- VRNA Nasdaq
- Market Cap
- FYBR 9.1B
- VRNA 8.3B
- IPO Year
- FYBR N/A
- VRNA 2017
- Fundamental
- Price
- FYBR $36.60
- VRNA $105.18
- Analyst Decision
- FYBR Buy
- VRNA Buy
- Analyst Count
- FYBR 8
- VRNA 11
- Target Price
- FYBR $35.80
- VRNA $114.10
- AVG Volume (30 Days)
- FYBR 2.7M
- VRNA 8.2M
- Earning Date
- FYBR 07-29-2025
- VRNA 08-11-2025
- Dividend Yield
- FYBR N/A
- VRNA N/A
- EPS Growth
- FYBR N/A
- VRNA N/A
- EPS
- FYBR N/A
- VRNA N/A
- Revenue
- FYBR $6,045,000,000.00
- VRNA $118,535,000.00
- Revenue This Year
- FYBR $4.85
- VRNA $893.95
- Revenue Next Year
- FYBR $3.37
- VRNA $73.76
- P/E Ratio
- FYBR N/A
- VRNA N/A
- Revenue Growth
- FYBR 4.15
- VRNA N/A
- 52 Week Low
- FYBR $24.43
- VRNA $18.51
- 52 Week High
- FYBR $39.21
- VRNA $105.50
- Technical
- Relative Strength Index (RSI)
- FYBR 48.24
- VRNA 70.25
- Support Level
- FYBR $36.39
- VRNA $104.58
- Resistance Level
- FYBR $36.89
- VRNA $105.31
- Average True Range (ATR)
- FYBR 0.17
- VRNA 0.22
- MACD
- FYBR -0.04
- VRNA -0.64
- Stochastic Oscillator
- FYBR 30.43
- VRNA 60.49
About FYBR Frontier Communications Parent Inc.
Frontier Communications Parent Inc is a communications and technology provider offering broadband services. The company provides voice services, including data-based voice over Internet protocol (VoIP) and unified communications as a service (UCaaS), as well as long-distance and voice messaging services, to consumer and business customers in all its markets.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.